Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Talisman: Prophylaxis for Talquetamab-related Dysgeusia in Multiple Myeloma
NCT06500884Phase 2Recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Aug 2024
- Primary completion
- May 2030
- Modality
- Bispecific Antibodies, Trispecific Antibodies, T-cell Engagers
- Countries
- 7
01
Overview
Phase 2, randomised, open-label trial of zinc gluconate and ramantamig in multiple myeloma (MM) (6 cohorts), sponsored by Janssen Pharmaceutical. Primary endpoints: Percentage of Participants With Occurrence of Dysgeusia as Assessed by the Total Waterless Empirical Taste Test (WETT) up to 12 months, Percentage of Participants With Occurrence of Severe Dysgeusia up to 12 months and 2 more. Started Aug 2024; status: recruiting.
02
Drugs
zinc gluconateramantamig
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT06500884.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06500884.